INTRODUCTION
Systemic Lupus Erythematosus (SLE) is an autoimmune multi system disease that causes dysregulation of immune system leading to damage of various tissues and organs. Although it predominantly affects women of childbearing age, it can occur in all age groups, with pediatric onset SLE (p-SLE) comprising 15-20% of all cases. p-SLE is often a more severe disease with involvement of renal, neurological and hematologic systems leading to permanent damage when compared to adult-onset SLE patients (a-SLE). The upper age limit for p-SLE is not clearly defined, with most studies quoting the...
upper age limit cut off of 16 or 18 years. Data collected from US Medicaid Beneficiary Population for the period 2000-2004, showed an annual incidence of p-SLE of 2.22 per 100,000 children and a prevalence of 9.73 per 100,000 children, between the ages of 3 to 18 years. SLE is more female-centric in adult onset SLE (a-SLE), female to male ratio being 9:1 while in p-SLE this ratio decreases to 4:5:1.2

As in Rheumatoid arthritis, a treat to target approach is now advocated for SLE.3 In order to achieve this it is fundamental to both diagnose, as well as to correctly recognize disease activity or flare. For the diagnosis of SLE, Anti-nuclear antibodies (ANA) by immunofluorescence technique (IFA), with a sensitivity of 90-98%, is considered a gold standard screening test, its specificity is only 78-83%.4 Anti-double stranded DNA antibody (Anti-dsDNA) another antibody commonly detected in SLE, it has specificity of 97% but sensitivity of 60%.5 By combining these two antibody, we get a higher sensitivity and specificity for the diagnosis of SLE.

For the identification of disease activity there are certain disease measurement tools, among them SLE Disease Activity Index (SLEDAI) is a global score used to assess the severity of disease of the previous ten days, contain both clinical and laboratory parameters.6 It is shown to be an excellent tool in assessing the disease activity in p-SLE patients because it is concise and easy to use and has shown remarkable psychometric properties in validation.7 Different clinical features like malar rash, oral ulcers and laboratory parameters like hematuria, proteinuria, low complement levels (especially of C3), and an elevated ESR have shown to be associated with increase disease activity.8

The aim of this study was to see the association of SLEDAI score with the clinical and laboratory presentation of p-SLE in a Pakistani population presenting to a tertiary care Rheumatology Department. This is a unique study as it is the first to assess disease activity in p-SLE by calculating SLEDAI score and correlates it with clinico-laboratory parameters; all-previous studies published locally, and these are scarce, have only highlighted the clinical and laboratory features in p-SLE.9,10

METHODS

This cross-sectional study was carried out in the Rheumatology Department of Fatima Memorial Hospital (FMH), Lahore, over a period of three months from November 2018 to January 2019, after approval (Ref. No. FMH-09-2018-IRB-494-M, dated on October 25, 2018) from Institutional Review Board (IRB). A total of 23 patients diagnosed with p-SLE below or at the age of 18 years, irrespective of their current age, of either gender, fulfilling 2012 criteria of Systemic Lupus International Collaborating Clinics (SLICC) were enrolled, patients with MCTD, overlap syndrome were excluded. No laboratory tests/ intervention has been done for the purpose of this study, it was a standard of care provided to the patients and after informed consent (Appendix I) from patient or parent/guardian (in case of a minor), their medical records were reviewed for clinical symptoms, and laboratory investigations comprising of erythrocyte sedimentation rate (ESR), hemoglobin level, total leucocyte count (TLC), platelet count, urine complete analysis for proteinuria (by dipstick method), hematuria (> 5 RBCs), pyuria (>5 WBCs) on high power field and spot urine for protein to creatinine ratio; SLE related specific tests, including ANA by IFA, Anti-dsDNA by ELISA technique, complement C3 and C4 levels and histopathology. SLEDAI score (Appendix I) was calculated, patients with SLEDAI score ≥ 6 will be defined as having active disease while those with score < 6 will be considered as having inactive disease.8 All these parameters were entered in a pre-designed proforma.

Data were entered and analyzed on SPSS version 23. Mean and standard deviation were calculated for numerical variables while frequencies and percentages were calculated for categorical variables. Non-parametric Spearman correlation and chi-square between SLEDAI score and laboratory investigation were applied to see any association while non-parametric Man Whitney test was applied to see any statistically significant difference between patients having clinical symptoms with high or low SLEDAI score.

RESULTS

A total of 23 patients were enrolled, in which 91.3% (n=21) were females and 8.7% (n=2) were male, with a female to male ratio of 21:2. The mean age of patients at presentation was 15.4 years ±5, while mean age at diagnosis of SLE was 11 years ±4. Consanguinity between the parents of patients was present in 47.8% (n=11). Mean age of menarche was 12.8±0.8 years. The median of duration of disease, which was ascertained by the onset of symptoms suggestive of SLE to the present time was 36.0 IQR 81.0 months i.e. approximately 3.5 years, with a minimum disease duration of one month to the maximum disease duration of 120 months i.e. 10 years: and most patients i.e. 47.8% (n=11) had disease duration between 1 to 5 years.
At presentation patients had symptoms of fever 43.5% (n=10), mucocutaneous symptoms 65.2% (n=15) that comprised of oral ulcers 26.1% (n=6), malar rash 39.2% (n=9), discoid rash 4.3% (n=1), livedo reticularis 8.7% (n=2), and photosensitivity 30.4% (n=7). Renal involvement was found in 26.1% (n=6) of patients, these patients presented with proteinuria, pyuria and hematuria. On renal biopsy 66.6% (n=4) had WHO class IV diffuse proliferative while 33.3% (n=2) had class V membranous lupus nephritis. Hematological involvement was seen in 69.6% (n=16), patients, as anemia, thrombocytopenia and leucopenia. Serositis was present in 8.7% (n=2) of patients in which one patient presented with pericardial effusion and one with ascites. Neurological involvement was present in 13% (n=3) of patients in the form of seizures (n=1), stroke (n=1) and optic neuritis (n=1). They were diagnose as having NPSLE after complete physical examination as well as laboratory and radiological workup including MRI Brain along with EEG and Optical Coherence Tomography (OCT) in patients with seizures and optic neuritis respectively.

On autoimmune workup ANA by IFA was positive in all patients while Anti-dsDNA was positive in 78.3% (n=18) of patients. Other laboratory workup showed acute phase reactant ESR was raised in most of the patients. Complements were low in 65% (n=13), normal in 35% (n=7) while not done in three patients. SLEDAI score was ≥6 in 87% (n=20) while less than 6 in 13% (n=3) of patients. For further details. Table-I.

In our study we have found significant association between SLEDAI and certain laboratory parameters. It was shown that elevated ESR (r=0.48, p=0.02), Anti-dsDNA (r=0.44, p=0.05) and low complement levels (p=0.03) were significantly positively correlated, while hemoglobin (r= -0.43, p=0.04) was significantly negatively correlated with the SLEDAI score, while platelets count value, leucocyte count and protein to creatinine ratio did not show any significant association. Table-II, Fig.1

### Table-I: Frequency of clinical, laboratory parameters and SLEDAI score.

| Features            | n (%) | 23 |
|---------------------|-------|-----|
| **Age at diagnosis** |       |     |
| < 11 years          | 7     | 30.4 |
| 11-14               | 7     | 30.4 |
| 15-18               | 9     | 39.2 |
| **Gender**          |       |     |
| Female              | 21    | 91.3 |
| Male                | 2     | 8.7  |
| **Symptoms/Signs at presentation** | | |
| Fever               | 10    | 43.5 |
| Mucocutaneous       | 15    | 65.2 |
| Hair loss           | 10    | 43.5 |
| Arthritis           | 10    | 43.5 |
| Renal involvement   | 6     | 26.1 |
| Hematological       | 16    | 69.6 |
| Neurological        | 3     | 13.0 |
| Serositis           | 2     | 8.7  |
| Raynaud’s           | 3     | 13.0 |
| **Laboratory parameters** | | |
| Anemia              | 12    | 52.2 |
| Leucopenia          | 3     | 13.0 |
| Thrombocytopenia    | 3     | 13.0 |
| Proteinuria         | 6     | 26.1 |
| Hematuria           | 2     | 8.7  |
| Pyuria              | 6     | 26.1 |
| Raised ESR          | 18    | 78.3 |
| **Immunological parameters** | | |
| Presence of ANA     | 23    | 100  |
| Presence of Anti-dsDNA | 18 | 78.3 |
| Low complements     | 13    | 65   |
| **SLEDAI score**    |       |     |
| Active (≥6)         | 20    | 87.0 |
| Inactive (<6)       | 3     | 13.0 |

### Table-II: Correlation of SLEDAI score with laboratory parameters in p-SLE Patients (n=23).

| Laboratory Parameters | Spearman’s correlation with P value Sledai Score (r) |
|-----------------------|-----------------------------------------------------|
| Hemoglobin value      | -0.414                                              |
| Leucocyte count value | 0.378                                               |
| Platelet count value  | 0.152                                               |
| ESR value             | 0.459                                               |
| Protein to creatinine (P.C.) ratio value | 0.029                                           |
| Anti-dsDNA titer value| 0.405                                               |

*Correlation is significant at the 0.05 level (2-tailed).
In this study we have found significant differences in SLEDAI scores of different clinical manifestations. Average SLEDAI score was higher in individuals presenting with renal involvement \((p=0.06)\) as evidenced by proteinuria, pyuria and hematuria, followed by neurological symptoms and presence of serositis, while patients with mucocutaneous symptoms, arthritis and hematological involvement have less disease activity scores. Table-III.

**DISCUSSION**

In this study 21 patients were female with a female to male ratio of 10.5:1, this ratio is higher to the ratio reported in p-SLE i.e. 4-5:1, and closer to the ratio seen in adult SLE i.e. 9:1;2 this may be because this study was conducted in a primarily adult rheumatology set up, although in dedicated pediatric clinics, with 21.7% of patients being above 18 years of age. Mean age at diagnosis of disease was 11±4 years, which is similar to another study conducted in Pakistan9 as well as studies conducted in Asia that reported mean age at diagnosis between 8.6-13.5 years.11

Hematological manifestations were the most common manifestations seen in South East Asia region1, similarly 69.9% of our patients presented with hematological involvement; Anemia being the commonest manifestation at 52.2%, close to the frequency of anemia seen in p-SLE population in Pakistan9 and associated with increased SLEDAI score therefor it is an alert to contemplate flare in p-SLE patients presenting with anemia.

p-SLE is a major cause of mortality and morbidity in the young population12, although its survival has been improved in past few years because of early diagnosis and recognition of disease activity13, but the survival seen in a Pakistani SLE cohort was less as compared to that of reported Caucasian and Asian series.14 Among its clinical symptoms renal involvement is a common feature with a frequency of 37-82%.15 The proportion of SLE patients who develop nephritis is higher in Afro-Caribbean’s and Indo-Asians than in whites16, contrary in our patient’s cohort renal involvement was slightly less i.e. 26.1%. It has been estimated that proliferative nephritis class IV is the most common histopathology identified in p-SLE and the most aggressive one1 likewise 66% of our patients had WHO class IV proliferative nephritis. It has been reported that p-SLE with Lupus Nephritis has high disease activity,15 similar results were found in this study, the average SLEDAI score was higher in patients presenting with renal involvement \((p=0.06)\) as shown in Table-III. Therefor early diagnosis and effective treatment is necessary in the management of these patients in order to improve long term survival.

Auto immune profile including ANA by IFA was positive in all patients, thus being consistent with its sensitivity of 90-98% in SLE4, while Anti-dsDNA was positive in 78.3% of patients, a result similar to other studies conducted in Pakistan and South East Asia.1,8,9

In a-SLE, a rise in Anti-dsDNA titer seen with higher disease activity in most but not in all cases17, this principal is also followed in p-SLE18, there are studies suggesting a positive correlation between disease activity and titer of Anti-dsDNA.19,20 Low complements levels are also associated with disease flare.8,20,21 Similar results were found in our patients, increased SLEDAI scores were significantly associated with elevated Anti-dsDNA titer and low complement levels. Inflammatory marker like ESR often increases in SLE patients with active disease,8,22 likewise in this study, elevated ESR is associated with increased disease activity scores. Above mentioned results suggest that these laboratory parameters are the useful investigation tools for assessing disease activity and predicting SLE flares.

There was no significant association found between any clinical symptoms and SLEDAI score, however, the average SLEDAI score was significantly higher in patients with Lupus nephritis (Table-III).

There is no previous data available on disease activity in p-SLE and its association with clinical and laboratory parameters in Pakistan, this study will guide further research in this field. **Limitations of the study:** It includes the small cohort, conducted at a single center, and a tertiary care referral bias.

**CONCLUSION**

Elevated Anti-dsDNA titer, ESR, low complements and hemoglobin were significantly associated with
APPENDIX-I
Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Score.
Check box: If descriptor is present at the time of visit or in the proceeding 10 days.

| Wt | Present | Descriptor        | Definition                                                                 |
|----|---------|-------------------|-----------------------------------------------------------------------------|
| 8  | □       | Seizure           | Recent onset. Exclude metabolic, infectious or drug cause                     |
|    |         |                   | Altered ability to function in normal activity due to severe disturbance in   |
|    |         |                   | the perception of reality. Include hallucinations, incoherence, marked loose  |
|    |         |                   | associations, impoverished thought content, marked illogical thinking, bizarre,|
|    |         |                   | disorganized, or catatonic behavior. Excluded uremia and drug causes.        |
| 8  | □       | Psychosis         | Altered mental function with impaired orientation, memory or other intelligent|
|    |         |                   | function, with rapid onset fluctuating clinical features. Include clouding of|
|    |         |                   | consciousness with reduced capacity to focus, and inability to sustain attention|
|    |         |                   | to environment, plus at least two of the following: perceptual disturbance,   |
|    |         |                   | incoherent speech, insomnia or daytime drowsiness, or increased or decreased   |
|    |         |                   | psychomotor activity. Exclude metabolic, infectious or drug causes.           |
| 8  | □       | Organic Brain     | Altered mental function with impaired orientation, memory or other intelligent|
|    |         | Syndrome          | function, with rapid onset fluctuating clinical features. Include clouding of|
|    |         |                   | consciousness with reduced capacity to focus, and inability to sustain attention|
|    |         |                   | to environment, plus at least two of the following: perceptual disturbance,   |
|    |         |                   | incoherent speech, insomnia or daytime drowsiness, or increased or decreased   |
|    |         |                   | psychomotor activity. Exclude metabolic, infectious or drug causes.           |
| 8  | □       | Visual Disturbance| Retinal changes of SLE. Include cytoid bodies, retinal hemorrhages, serous     |
|    |         |                   | exudate or hemorrhages in the choroids, or optic neuritis. Exclude hypertension,|
|    |         |                   | infection, or drug causes.                                                  |
| 8  | □       | Cranial Nerve Disorder | New onset of sensory or motor neuropathy involving cranial nerves.         |
| 8  | □       | Lupus Headache    | Severe persistent headache: may be migrainous, but must be nonresponsive to  |
|    |         |                   | narcotic analgesia.                                                         |
| 8  | □       | CVA               | New onset of cerebrovascular accident(s). Exclude arteriosclerosis          |
| 8  | □       | Vasculitis        | Ulceration, gangrene, tender finger nodules, periungual, infarction, splinter|
|    |         |                   | hemorrhages, or biopsy or angiogram proof of vasculitis                     |
| 4  | □       | Arthritis         | More than 2 joints with pain and signs of inflammation (i.e. tenderness, swelling,|
|    |         |                   | or effusion).                                                               |
| 4  | □       | Myositis          | Proximal muscle aching/weakness, associated with elevated creatine           |
|    |         |                   | phosphokinase/adolase or electromyogram changes or a biopsy showing myositis.|
| 4  | □       | Urinary Casts     | Heme-granular or red blood cell casts                                         |
| 4  | □       | Hematuria         | >5 red blood cells/high power field. Exclude stone, infection or other cause.|
| 4  | □       | Proteinuria       | >0.5 gm/24 hours. New onset or recent increase of more than 0.5 gm/24 hours.|
| 4  | □       | Pyuria            | >5 white blood cells/high power field. Exclude infection.                     |
| 2  | □       | New Rash          | New onset or recurrence of inflammatory type rash.                          |
| 2  | □       | Alopecia          | New onset or recurrence of abnormal, patchy or diffuse loss of hair.        |
| 2  | □       | Mucosal Ulcers    | New onset or recurrence of oral or nasal ulcerations                        |
| 2  | □       | Pleurisy          | Pleuritic chest pain with pleural rub or effusion, or pleuritic thickening.   |
| 2  | □       | Pericarditis      | Pericardial pain with at least 1 of the following: rub, effusion, or         |
|    |         |                   | electrocardiogram confirmation.                                             |
| 2  | □       | Low Complement    | Decrease in CH50, C3, or C4 below the lower limit of normal for testing       |
|    |         |                   | laboratory.                                                                 |
| 2  | □       | Increased DNA     | >25% binding by Farr assay or above normal range for testing laboratory.     |
| 1  | □       | Fever             | >38°C. Exclude infectious cause                                             |
| 1  | □       | Thrombocytopenia  | <100,000 platelets/mm3                                                      |
| 1  | □       | Leukopenia        | <3,000 White blood cell/mm3. Exclude drug causes.                           |

TOTAL SCORE (Sum of weights next to descriptors marked present).
high SLEDAI scores. The average SLEDAI score was significantly higher in our Lupus nephritis patients, and we recommend that all pediatric lupus patients should have a Urine dipstick done routinely in outpatient, and SLEDAI scores calculated to enable stringent disease monitoring and treatment.

**Acknowledgement:** We would like to thank Prof. Nighat Mir Ahmad, Dr. Mohammad Ahmed Saeed, for their help and assistance to improve the manuscript. We would also like to thank our colleagues Dr. Haseeb Ahmed Khan, Dr. Zeeshan Aslam, Dr. Asadullah Khan, Dr. Naveed Aslam Lashiri, Dr. Ziauddin, Dr. Faq and Dr. Farhan Bashir for their support throughout this research.

**Grant support, Financial Disclosures & Conflict of Interest:** None.

**REFERENCES**

1. JHT Tan, SF Hoh, MMT Win, Chan YH, Das L, Arkachaisri T. Childhood-onset systemic lupus erythematosus in Singapore: Clinical phenotypes, disease activity, damage and autoantibody profiles. Lupus. 2015;24(9):998-1005. doi: 10.1177/0961203315584413

2. Hiraki LT, Feldman CH, Liu Jun, Alarcon GS, Fischer MA, Winkelmayer WC, et al. Prevalence, Incidence and Demographics of Systemic Lupus Erythematosus and Lupus Nephritis from 2000 to 2004 among children in the US Medicaid Beneficiary Population. Arthritis Rheum. 2012;64:2669-2676. doi: 10.1002/art.34472

3. Van Vollenhoven RF, Mosca M, Bertisias G, Isenberg D, Ravelli A. Measures of disease activity and damage in pediatric systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-967. doi: 10.1136/annrheumdis-2013-205139

4. Sridaran S, Ansari MQ. Sensitivity and Specificity of the Anti-Nuclear Antibody (ANA) indirect immunofluorescent assay (IIFA) at varying titers for diagnosing SLE: An evidence based approach for assessing the utility of ANA tests in the clinical setting. Austin J Pathol Lab Med. 2015;2(1):1014.

5. Wichainun R, Kasitanon N, Wangkaew S, Hongsongkiat S, Sukitawut W, Louthrenoo W. Sensitivity and specificity of ANA and anti-dsDNA in the diagnosis of systemic lupus erythematosus: A comparison using control sera obtained from healthy individuals and patients with multiple medical problems. Asian Pac J Allergy Immunol. 2013;31(4):292-298. doi: 10.12932/AP0272.31.4.2013

6. Mikdash J, Nived O. Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research. Arthritis Res Ther. 2015;17(1):183. doi: 10.1186/s13075-015-0702-6

7. Lattanzi B, Consolaro A, Solari N, Ruperto N, Martini A, Ravelli A. Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician’s Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI). Arthritis Care Res (Hoboken). 2011;63(11):112-117. doi: 10.1002/acr.20623

8. Nazri SKSM, Wong KK, Hamid WZWA. Pediatric systemic lupus erythematosus. Retrospective analysis of clinicolaboratory parameters and their association with Systemic Lupus Erythematosus Disease Activity Index score. Saudi Med J. 2018;39(6):627-631. doi: 10.15577/smj.2018.622112

9. Ahmed S, Ali SR, Karim F, Ishaque S, Qaiser I, Nayani K, et al. Childhood-onset systemic lupus erythematosus: An experience of tertiary care hospital: A cohort study. J Coll Physicians Surg Pak. 2018;28(5):365-369.

10. Nazir L, Umer UP, Hanoon W, Saad Salim M, Jawed M. Paediatric lupus is a great mimicker, a case series. Int J Rheum Dis. 2017;20(Suppl 1):17-131.

11. Aggarwal A, Srivastava P. Childhood onset systemic lupus erythematosus: how is it different from adult SLE? Int J Rheum Dis. 2015;18(2):182-191. doi: 10.1111/1756-185X.12419

12. Petri M, Perez-Guthmann S, Longenecker JC, Hochberg M. Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med. 1991;91:345-353.

13. Chan PC, Yu CH, Yeh KW, Horng JT, Huang JL. Comorbidities of pediatric lupus erythematosus: A 6-year nationwide population –based study. J Microbiol Immunol Infect. 2016;49(2):257-263. doi: 10.1016/j.jmii.2014.05.001

14. Rabbani MA, Habib HB, Islam M, Ahmad B, Majid S, Saeed W, et al. Survival analysis and prognostic indicators of systemic lupus erythematosus in Pakistani patients. Lupus. 2009;18:848-855. doi: 10.1177/0961203309103410

15. Szymaniak-Grzelak H, Kuzma-Mroczkowska E, Maldyj K, Panczyk-Tomaszewska M. Lupus nephritis in children - 10 years’ experience. Cent Eur J Immunol. 2016;41(3):248-254. doi: 10.5114/cej.2016.63123

16. Patel M, Clarke AM, Bruce IN, Symmons DP. The prevalence and incidence of biopsy-proven lupus nephritis in the UK: Evidence of an ethnic gradient. Arthritis Rheum. 2006;54(9):2963-2969.

17. Gheita TA, Abaza NM, Hammam M, Mohamed AAA, El-Gazzar II, Eissa AH. Anti-dsDNA titer in female systemic lupus erythematosus patients: Relation to disease manifestations, damage and antiphospholipid antibodies. Lupus. 2018;27(7):1081-1087. doi: 10.1177/0961203318760209

18. Mina R, Brunner HI. Pediatric Lupus –Are there differences in presentation, genetics, response to therapy, damage accrual compared to adult Lupus. Rheum Dis Clin North Am. 2010;36(1):53-90. doi: 10.1016/j.rdc.2009.12.012

19. Zivkovic V, Stankovic A, Cvetkovic T, Mitic B, Kostic S, Nedovic J, et al. Anti-dsDNA, Anti-Nucleosome and Anti-C1q antibodies as disease activity markers in patients with Systemic lupus erythematosus. Srp Arh Celok Lek. 2014;142(7-8):431-436.

20. Narayanan K, Marwaha V, Shannuganandan K, Shankar S. Correlation between systemic lupus erythematosus disease activity index, C3, C4 and Anti-dsDNA antibodies. Med J Armed Forces India. 2010;66(2):102-107. doi: 10.1016/j.mjafi.2009.12.012

21. Amer HM. Clinical presentation of pediatric SLE at outpatient clinic. MOJ Orthop Rheumatol. 2015;2:00032. doi: 10.15406/mojorh.2015.02.00032

22. Amer HM. Clinical presentation of pediatric SLE at outpatient clinic. MOJ Orthop Rheumatol. 2015;2:00032. doi: 10.15406/mojorh.2015.02.00032

**Author’s Contribution:**

RS, SB & SEAK conceived the study. RS Prepared the manuscript, did data collection, statistical analysis and manuscript writing; & responsible for the accuracy of the work. MKHR did data collection and manuscript writing. SF did review and final approval of manuscript.